NEW YORK (Reuters Health) - Colestimide, a resin that binds and eliminates bile acids, seems to be an effective treatment for obesity and type 2 diabetes -- at least in mice -- according to a report ...
Habegger is a professor in the UAB Department of Medicine Division of Endocrinology, Diabetes and Metabolism and also a scientist in the UAB Nutrition Obesity Research Center who studies how glucagon ...
PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety ...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as ...
• Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones • Advances Travere’s strategy to deliver new treatment standards from its ...
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
The target LDL-C level is progressively lower as the risk for CHD increases. The measured LDL-C level at which drug therapy should be initiated also is lower asthe risk for CHD increases. For example, ...
In a study published in Nature on January 28, a research team led by Eric H. Xu (Xu Huaqiang) from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, along with Ma Xiong from ...
Older men and women with coronary artery disease, prior stroke, peripheral arterial disease, and extracranial carotid arterial disease with a serum low-density lipoprotein (LDL) cholesterol >125 mg/dL ...
ONE of the most frustrating features of primary biliary cirrhosis is pruritus, often so intense and unrelenting that the victim seriously contemplates suicide. 1 Such patients suffer from chronic ...
• Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones • Advances Travere’s strategy to deliver new treatment standards from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results